Comparing CDK4/6 inhibitors after surgery for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares two types of CDK4/6 inhibitor pills (dalpiciclib vs. abemaciclib or ribociclib) taken after surgery for early-stage, hormone-positive, HER2-negative breast cancer. The goal is to see which is better tolerated and may help lower the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and had stage II or III breast cancer.
- Your cancer was removed by surgery, and it was hormone receptor-positive (HR+) and HER2-negative.
- you had at least 4 lymph nodes with cancer, or 1–3 lymph nodes plus a high-risk feature (like a large tumor or high Ki-67).
- You finished chemotherapy at least 3 weeks ago, or radiotherapy at least 2 weeks ago.
- You have not had prior treatment with a CDK4/6 inhibitor (like Ibrance, Kisqali, Verzenio).
- You have no evidence of cancer spread (metastasis) and are generally in good health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This study tests a new combination of two medications given before surgery for stage II-III hormone-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes, possibly making surgery more successful.
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.